Affinity Asset Advisors LLC Sells 646,500 Shares of Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Affinity Asset Advisors LLC reduced its holdings in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 41.8% in the 2nd quarter, Holdings Channel.com reports. The fund owned 900,162 shares of the company’s stock after selling 646,500 shares during the period. Centessa Pharmaceuticals makes up approximately 1.6% of Affinity Asset Advisors LLC’s portfolio, making the stock its 20th largest position. Affinity Asset Advisors LLC’s holdings in Centessa Pharmaceuticals were worth $11,828,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the business. Marshall Wace LLP lifted its position in Centessa Pharmaceuticals by 152.4% during the 2nd quarter. Marshall Wace LLP now owns 343,318 shares of the company’s stock worth $4,511,000 after buying an additional 207,291 shares in the last quarter. Saturn V Capital Management LP increased its position in shares of Centessa Pharmaceuticals by 76.8% in the second quarter. Saturn V Capital Management LP now owns 793,327 shares of the company’s stock valued at $10,424,000 after acquiring an additional 344,635 shares during the last quarter. OMERS ADMINISTRATION Corp bought a new stake in shares of Centessa Pharmaceuticals during the 2nd quarter worth approximately $725,000. Meridian Wealth Partners LLC bought a new stake in Centessa Pharmaceuticals during the second quarter worth $501,000. Finally, American Century Companies Inc. lifted its stake in Centessa Pharmaceuticals by 3.5% in the second quarter. American Century Companies Inc. now owns 1,130,708 shares of the company’s stock valued at $14,858,000 after acquiring an additional 37,954 shares during the last quarter. Institutional investors own 82.01% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, October 27th. Guggenheim raised their price objective on shares of Centessa Pharmaceuticals from $28.00 to $43.00 and gave the stock a “buy” rating in a research report on Tuesday, November 18th. Oppenheimer started coverage on shares of Centessa Pharmaceuticals in a research report on Friday, August 29th. They issued an “outperform” rating and a $40.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Chardan Capital upgraded shares of Centessa Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, November 19th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $35.50.

Insider Buying and Selling

In other Centessa Pharmaceuticals news, insider Mario Alberto Accardi sold 8,172 shares of the business’s stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $21.40, for a total value of $174,880.80. Following the transaction, the insider directly owned 197,394 shares of the company’s stock, valued at approximately $4,224,231.60. The trade was a 3.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CTO Tia L. Bush sold 40,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $26.00, for a total transaction of $1,040,000.00. Following the sale, the chief technology officer directly owned 121,503 shares of the company’s stock, valued at approximately $3,159,078. This trade represents a 24.77% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 179,964 shares of company stock valued at $4,106,481 over the last quarter. Insiders own 7.09% of the company’s stock.

Centessa Pharmaceuticals Stock Up 1.2%

Shares of NASDAQ CNTA opened at $29.91 on Friday. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.56 and a quick ratio of 10.57. Centessa Pharmaceuticals PLC Sponsored ADR has a 1 year low of $9.60 and a 1 year high of $30.00. The firm has a market cap of $4.02 billion, a PE ratio of -16.34 and a beta of 1.55. The company has a 50 day simple moving average of $25.09 and a 200 day simple moving average of $19.15.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.02). On average, research analysts forecast that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current year.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.